At the request of the Association Française des Syndromes de Marfan et Apparentés (AssoMarfans), Ludivine has recorded a video and we are organizing various webinar sessions to help people who wish to join the GEMS study (https://www.101gems.be/site). Here is the e-mail sent by AssoMarfans to its members: Advance research on Marfan syndrome [...].
On September 16, 2022, Romain was invited to present to the 'Marfan Europe Network' (M.E.N.) the progress made by the 101 Marfan Genomes Project since the previous network meeting in Drammen in September 2019. It was an excellent opportunity to give an update on the implementation of the biobank (BioB) and the Genomic [...]
The F101G was assisted by three computer scientists to develop three new Apps to facilitate research in the field of rare diseases (GEMS pilot project) and to make the results of a bioinformatics tool using artificial intelligence (GEMVAP) available to the general public. This successful collaboration was organised by mic.brussels (Microsoft/Region of Brussels) and the [...].
On December 16, 2020, Professor Bart Loeys, a pediatric cardio-geneticist from the University of Antwerp, world-renowned specialist in Marfan syndrome and related diseases (such as Loeys-Dietz syndrome), co-Chairman of the Scientific Committee of Fondation 101 Génomes and leader of the GEMS project, received from His Majesty the King the prestigious [...].
700,000 euros to finance the Ghent & Antwerp teams working on GEMS! On December 16, 2020, Professors Bart Loeys and Paul Coucke have both received more than 700,000 euros in funding from the Fonds Wetenschappelijk Onderzoek (FWO) to work in the laboratory on the F101G flagship project: the GEMS! project. This is fantastic! […]
On October 26, 2020, Fondation 101 Génomes signed a Matching Gifts agreement with a partner who wishes to finance the GEMS project with 75,000 euros over three years. This partner will therefore double all donations made to Fondation 101 Génomes for GEMS research over three years. […]
GEMS stands for Genome-wide Epistasis for cardiovascular severity in Marfan Study. The objective of GEMS is to identify protective modifier genes (= epistatic genes) within the whole human genome that can explain the variability in cardiovascular severity found in individuals with Marfan syndrome. Such a discovery would make it possible to consider [...].
You must be connected to post a comment.